Has Delmer Montoya Motino, MD received payments from drug or device companies?

Yes. Drug and device makers reported $93,481 in general payments to Delmer Montoya Motino, MD across 572 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Delmer Montoya Motino, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Delmer Montoya Motino, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Delmer Montoya Motino, MD

Medical Oncology · Tucson, AZNPI 1740668383

Payments from drug & device makers

$93,481in general payments, 2019–2025

Across 572 payments — averaging $163.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron$40K
Janssen Research & Development, LLC$28K
Seagen Inc.$5K
AstraZeneca$5K
Karyopharm Therapeutics Inc.$3K
Daiichi Sankyo Inc.$2K
plus $11K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron	12	$39,800
Janssen Research & Development, LLC	7	$27,910
Seagen Inc.	15	$5,184
AstraZeneca(2 entities)	51	$4,594
Karyopharm Therapeutics Inc.	9	$2,912
Daiichi Sankyo Inc.	20	$1,779
Regeneron Healthcare Solutions, Inc.	18	$1,002
Johnson & Johnson(2 entities)	23	$914
Pfizer	42	$678
Bristol Myers Squibb	40	$618
Sumitomo Pharma America, Inc.	22	$579
Novartis	30	$541
Gilead(2 entities)	22	$477
Incyte Corporation	20	$426
Merck	18	$399
Eisai Inc.	15	$338
Genentech USA, Inc.	15	$324
Sanofi	13	$313
Amgen	10	$267
AVEO Pharmaceuticals, Inc.	5	$248
Bayer	14	$242
GSK	12	$229
Pharmacosmos Therapeutics Inc.	6	$224
AbbVie	9	$208
Astellas Pharma US Inc	7	$203
Rigel Pharmaceuticals, Inc.	8	$200
Epizyme, Inc.	2	$197
Biontech SE	2	$194
Intuitive Surgical	1	$192
Sobi, Inc	5	$173
Array Biopharma Inc	9	$167
Genmab U.S., Inc.	6	$160
Ipsen Biopharmaceuticals, Inc	5	$155
Jazz Pharmaceuticals Inc.	2	$146
Exelixis Inc.	6	$138
Lilly USA, LLC	7	$118
Takeda Pharmaceuticals U.S.A., Inc.	7	$117
E.r. Squibb & Sons, L.L.C.	7	$108
Beigene USA, Inc.	5	$93
CTI Biopharma Corp.	3	$75
Blueprint Medicines Corporation	3	$73
Stemline Therapeutics Inc.	4	$71
Springworks Therapeutics, Inc.	3	$67
Pharmaessentia USA Corporation	3	$62
Caris MPI, Inc.	1	$59
Puma Biotechnology, Inc.	3	$56
ADC Therapeutics America, Inc.	3	$55
Myovant Sciences Inc.	3	$55
Mirati Therapeutics, Inc.	3	$54
Legend Biotech USA Inc.	2	$38
Sun Pharmaceutical Industries Inc.	2	$34
Boehringer Ingelheim	1	$26
Kyowa Kirin, Inc.	1	$21
Taiho Oncology, Inc.	1	$20
Deciphera Pharmaceuticals Inc.	1	$20
Servier Pharmaceuticals LLC	1	$19
EMD Serono, Inc.	1	$18
Recordati_rare_diseases_inc.	1	$18
Morphosys, US Inc.	1	$17
Acrotech Biopharma Inc.	1	$15

How this compares

$93,481 in reported general payments places this provider in the 60th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,239,839

Medicare patients

533

Services billed

112,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Tucson

Michael BookmanTucson$4.8M
Aparna NallagangulaTucson$304K
Gerald HaginTucson$1K
Leona DowneyTucson$50
Morris FineTucson$35
Erkut BorazanciScottsdale$3.5M
Daniel von HoffScottsdale$2.5M
Jason SalganickPhoenix$1.6M
Allan Espinosa MorazanPrescott$1.1M
Iyad HamarnehPrescott$855K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →